Zura Bio presents Phase 2 poster: Guggenheim targets Zura Bio stock at USD 20

Published on 10/20/2026 at 14:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zura Bio shared a Phase 2 poster on October 15, 2026. Zura Bio stock costs EUR 3.45 on October 20, 2026, with a USD 20 target.

Trial catalyst and valuation

Guggenheim maintained a USD 20 target on October 7, 2026.
The TibuSHIELD Phase 2 study covers 247 patients.
Zura Bio stock was trading at EUR 3.45 at 2:11 p.m. CEST at Lang & Schwarz on October 20, 2026.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio Limited (ISIN KYG9TY5A1016) was trading at EUR 3.45 at Lang & Schwarz on October 20, 2026, while its clinical program moved closer to a key Phase 2 readout. Zura Bio said on October 15, 2026, that it had presented a poster on the design of TibuSHIELD at the Fall Clinical Dermatology Conference.

The poster concerned tibulizumab, an investigational bispecific antibody designed to target IL-17 and BAFF in hidradenitis suppurativa. The company is testing the treatment in a 247-patient Phase 2 study, making the coming data release the central near-term issue for the stock.

Three milestones shape the setup

The recent sequence is clear. On August 11, 2026, Zura Bio reported a second-quarter net loss of USD 26.39 million, according to Trefis. On October 7, 2026, Yahoo Finance reported that Guggenheim reiterated a Buy rating and a USD 20 target. The October 15, 2026 poster then added a concrete update on the Phase 2 study design.

What does the target imply?

Guggenheim's USD 20 target is materially above the current euro quotation, but the currencies and venues differ, so the figures are not combined into a return calculation. The valuation rests on a binary clinical catalyst rather than commercial revenue: Zura Bio remains a clinical-stage immunology company with candidates for autoimmune and inflammatory diseases, including tibulizumab, according to its Zura Bio investor-relations profile.

Next dates for Zura Bio

MarketBeat lists November 12, 2026, as the estimated date for the third-quarter earnings report. The TibuSHIELD topline readout is expected in the fourth quarter of 2026, while the investor-relations profile says the NEXUS-PMR study is planned for initiation by year-end 2026.

Clinical timing drives the stock story

Zura Bio is listed on Nasdaq under ticker ZURA and operates in biotechnology. The October poster did not provide efficacy results, so the investment case still turns on whether the 247-patient trial produces a meaningful clinical signal when topline data arrive.

The further course of trading is shown by the continuously updated real-time quote of Zura Bio stock.